The arrival of amivantamab offers a exciting advance for patients battling cancers exhibiting c-MET dysregulation. This innovative molecule, a selective blocker of both MET kinase and human epidermal growth factor https://deaconyxkq175206.wikicommunications.com/7440453/amivantamab_a_potential_hope_for_c_met_driven_tumors